Raymond James reiterates Palvella stock Strong Buy on conference data

William Blair initiated coverage on Palvella Therapeutics (PVLA) with an Outperform rating and a $266 price target, citing its QTORIN platform. The stock, trading at $127.34, has risen 74% over the past year. Palvella reported a Q2 loss of $1.52 per share, wider than expected, but shares rose due to investor interest in its cash reserves and trial progress. The company expects FDA approval for its lead drug, QTORIN rapamycin, in early 2027, with projected U.S. sales of $800 million by 2032.

William Blair initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating, citing positive Phase III data for its lead product and an upcoming transition to commercial stage. Anthropic's Q3 2026 revenue rose 46% to $16.8B, but investors now discuss a $1.5T valuation, down from $2T, due to slowing growth and high costs ahead of its expected IPO.

Palvella Therapeutics (PVLA) will present pediatric data from its Phase 3 SELVA and Phase 2 TOIVA studies at the PeDRA conference, showing improvements in disease severity for microcystic lymphatic and cutaneous venous malformations. The company's investigational gel, QTORIN rapamycin, has no FDA-approved alternatives for these conditions.

Palvella Therapeutics (NASDAQ:PVLA) presented data from its Phase 3 SELVA study of QTORIN rapamycin gel, showing 95% of participants improved on the primary endpoint. The company also shared results from a pharmacokinetic substudy and a real-world claims analysis of DSAP patients. Palvella completed its FDA application for QTORIN in August 2026 and plans a Phase 2 trial for QTORIN pitavastatin in Q4 2026.

Palvella Therapeutics reported Phase 3 SELVA interview data showing improvements and high satisfaction with QTORIN rapamycin. The company also presented PK data with ≥40-fold lower exposure vs oral sirolimus and a claims analysis estimating 154,986 diagnosed DSAP patients in the U.S. according to the company.

Palvella Therapeutics (Nasdaq: PVLA) presented data at a dermatology conference. Phase 3 SELVA study results showed QTORIN™ rapamycin improved symptoms of microcystic lymphatic malformations (microcystic LMs) with high treatment satisfaction. A real-world claims analysis estimated 154,986 U.S. patients diagnosed with disseminated superficial actinic porokeratosis (DSAP) over eight years.